UNSPSC 51263148: Befunolol hydrochloride

This classification denotes a beta-adrenergic blocking agent and anti-glaucoma agent with the molecular formula C16H21NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B03Z2VY37I, chemically known as ethanone, 1-(7-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2-benzofuranyl)-, hydrochloride but more generally known as befunolol hydrochloride, which bears US NIH Compound Identifier 38286.

European Medicines Agency schedules Befunolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00686MIG. Most nations, for tariff and trade purposes, schedule befunolol hydrochloride under HS 29329985 and SITC 51569. As of Q4 2014, BEFUNOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)NCC(COC1CCCC2C1OC(C2)C(=O)C)O.CL.

UNSPSC 51263148 Befunolol hydrochloride is a Commodity code with a significant mismatch between its nominal pharmaceutical scope and recent state and local solicitation activity. The code title identifies a specific beta-blocker medication, yet recent postings under this code do not procure befunolol itself. Instead, Seminole County, Florida recently posted IFB 60459723LAS seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building and an initial two-year contract term with a one-year renewal option. The Texas Health and Human Services Commission simultaneously issued RFI HHS0017013 to gather market intelligence on direct-to-manufacturer prescription programs and pharmacy benefit management models, reflecting state-level interest in prescription fulfillment efficiency rather than procurement of a specific pharmaceutical compound. These opportunities suggest the code captures emergency-response pharmaceuticals and prescription-program infrastructure rather than the specific medication the code nominally identifies.

Issuing bodies posting under this code span county health departments and state health agencies. Seminole County, Florida represents the clearest recent activity at the county level; the Texas Health and Human Services Commission reflects state-level pharmacy benefit and acquisition strategy work. Geographic spread is limited in the recent record to Florida and Texas. The Seminole County IFB (due July 26, 2023, per the posted materials) established fixed-fee pricing on a unit-cost basis with E-Verify compliance and drug-free workplace certification required, and the Texas RFI (due April 3, 2026) functions as exploratory procurement to inform future formal solicitations without committed budget or award values. Neither opportunity specifies set-aside designations for disadvantaged enterprises, though the Seminole County contract notes potential FEMA funding, which introduces federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act.